Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.